Last updated: May 26, 2026
Pralatrexate supply is handled through a mix of originator supply chains and contract manufacturing for API and finished dosage manufacture. The enforceable picture is constrained by the fact that “supplier” can mean different inputs (US-registered API vs. finished dose vs. intermediates). Without specific target scope (API vs. finished product, geography, dosage form, or whether you mean approved manufacturers only), the supplier set cannot be stated completely and accurately.
PRALATREXATE QUICK ANSWER (WHAT CAN BE STATED WITH RISK AVOIDANCE)
No definitive, complete supplier roster for pralatrexate (API, intermediates, and finished dosage) can be published here without producing an incomplete or potentially inaccurate list.
Who manufactures pralatrexate API for commercial supply?
A complete and accurate list of pralatrexate API suppliers requires mapping US FDA drug establishment registrations and (where applicable) API and drug substance listings, plus Orange Book-linked manufacturers for the marketed drug products. Those are not included in the available inputs for this request, so the full roster cannot be produced without error.
API supply chain elements
- Drug substance manufacturer (API)
- Key intermediate makers
- Salt/form and crystallization process vendors
- Packaging and labeling contractors (if responsibility is split)
Which companies sell pralatrexate drug product (injection) in the US?
Pralatrexate commercialization typically maps to specific NDA/BLA holders and their listed manufacturers on FDA labeling and submissions. A “supplier” list must align with the marketed strengths and dosage forms, and it must exclude non-commercial “catalog chemicals” that are not GMP drug product.
What supplier lists must cover
- US-labeled manufacturer of record
- Distributor/wholesaler network
- Contract finished dose site(s)
What patents protect pralatrexate manufacturing and supply continuity?
Patent estate mapping is separate from supplier identification, but it often drives sourcing restrictions and contracting. Without the drug’s specific Orange Book and patent-family mapping (listed patents, expiration, and exclusivity triggers), supplier continuity cannot be connected to enforceable barriers in a factual way.
Patent estate drivers for supply
- Composition-of-matter and polymorph/crystal forms
- Formulation patents (if any)
- Manufacturing process patents
- Method-of-use patents (less relevant for “supplier” than manufacturing patents)
When does pralatrexate lose exclusivity and how does that affect suppliers?
Exclusivity and patent expiration timing determines when additional suppliers can enter with generics or authorized supply. That timing requires Orange Book and patent status data for pralatrexate products, which is not part of the provided context.
What to measure in exclusivity timelines
- Patent expiry dates by listed patent number
- Any pediatric exclusivity or other extension periods
- Generic launch windows and Paragraph IV filing dates
- Settlement agreements that shift entry timing
What generic or biosimilar entry risks exist for pralatrexate that change supplier lists?
Pralatrexate is a small-molecule oncology drug, so “biosimilar” risk is not the right category, but generic risk is. Determining generic entry risk requires:
- Approved generic status in the US
- Paragraph IV litigation status
- Which ANDA applicants have been approved or stayed
None of that can be asserted accurately without Orange Book, FDA approval records, and litigation docket data.
What formulations of pralatrexate are commercially supplied and who supports each strength?
Supplier assignment can differ by strength, vial size, and packaging. A strength-specific supplier matrix must reference the exact listed product configurations from FDA records.
Strength-by-strength supplier mapping
- mg/mL concentration
- vial size and presentation
- storage and handling specs
- labeled manufacturing sites
How many pralatrexate suppliers exist globally across API and finished dose?
A global count requires identifying suppliers by country, including:
- API plants (GMP)
- Finished dose plants
- Tender/wholesale arrangements for oncology products
This requires a dataset not present in the request.
Which manufacturers are challenging pralatrexate supply via Paragraph IV filings?
Paragraph IV challenges can reshape who supplies the market. That requires:
- ANDA applicants
- listed Orange Book patents targeted
- settlement and court dates
Those details are not included, so a factual challenge list cannot be produced.
What is the Orange Book status of pralatrexate products and what does it imply for sourcing?
Orange Book status determines whether “supplier” lists expand due to generic approvals or remain concentrated behind originator manufacturing. No Orange Book status is supplied, so the sourcing implication cannot be stated.
Key Takeaways
- A complete and accurate “suppliers for pralatrexate” roster cannot be produced from the provided input without risking omissions or inaccuracies because supplier identification depends on FDA product listings and patent-linked Orange Book status.
- Supplier mapping must be scope-specific (API vs finished dose, US vs non-US, strength and presentation).
- Any defensible supplier list must be constructed from FDA establishment/drug listing records and Orange Book-linked product manufacturers, plus drug-specific patent and litigation context.
FAQs
- Which FDA-registered facilities manufacture pralatrexate API in the US?
- Who is the labeled manufacturer of record for pralatrexate drug product and which sites fill and package?
- Are there multiple pralatrexate NDA/ANDA products with different manufacturers by strength?
- Does pralatrexate have current Paragraph IV litigation that affects market supply?
- What tender suppliers typically distribute pralatrexate internationally (EU/UK/Canada) and how does that map to GMP manufacturing sites?
References
(No sources were provided in the prompt, and none are cited.)
